Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC

• Ryo Toyozawa, MD,
• Naoki Haratake, MD, PhD,
• Gouji Toyokawa, MD, PhD,
• Taichi Matsubara, MD, PhD,
• Shinkichi Takamori, MD, PhD,
• Naoko Miura, MD,
• Masafumi Yamaguchi, MD, PhD,
• Mitsuhiro Takenoyama, MD, PhD,
• Takashi Seto, MD, PhD

Affiliations

Ryo Toyozawa, MD

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Naoki Haratake, MD, PhD

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Gouji Toyokawa, MD, PhD

Department of Thoracic Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

Taichi Matsubara, MD, PhD

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Shinkichi Takamori, MD, PhD

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Naoko Miura, MD

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Masafumi Yamaguchi, MD, PhD

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Mitsuhiro Takenoyama, MD, PhD

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Takashi Seto, MD, PhD

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; Corresponding author. Address for correspondence: Takashi Seto, MD, Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan.